PDS Biotechnology Crecimiento futuro

Future controles de criterios 0/6

Se prevé un crecimiento anual de los beneficios y los ingresos de PDS Biotechnology de 22.9% y 65% respectivamente, mientras que el BPA crecerá en un 28% al año.

Información clave

22.9%

Tasa de crecimiento de los beneficios

28.0%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	24.0%
Tasa de crecimiento de los ingresos	65.0%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Low
Última actualización	28 Mar 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

PDS Biotechnology: Promising Phase 2 With Cash Issues That Might Be Worth The Risk

Jan 13

PDS Biotech announces preliminary efficacy readout from phase 2 combo trial of PDS0101

Feb 03

PDS Biotechnology gives new CFO ~202K stock grant

Jan 06

PDS Biotech launches mid-stage PDS0101 combo trial in head & neck cancer

Nov 10

Previsiones de crecimiento de beneficios e ingresos

NasdaqCM:PDSB - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	25	-51	-48	9	3
12/31/2025	0	-64	-61	-37	4
12/31/2024	N/A	-51	-56	-43	5
12/31/2023	N/A	-43	-34	-34	N/A
9/30/2023	N/A	-51	-33	-33	N/A
6/30/2023	N/A	-48	-31	-31	N/A
3/31/2023	N/A	-42	-33	-33	N/A
12/31/2022	N/A	-41	-26	-26	N/A
9/30/2022	N/A	-28	-23	-23	N/A
6/30/2022	N/A	-28	-22	-22	N/A
3/31/2022	N/A	-22	-15	-15	N/A
12/31/2021	N/A	-17	-12	-12	N/A
9/30/2021	N/A	-15	-13	-13	N/A
6/30/2021	N/A	-12	-9	-9	N/A
3/31/2021	N/A	-14	-14	-14	N/A
12/31/2020	N/A	-15	-13	-13	N/A
9/30/2020	N/A	-15	-14	-14	N/A
6/30/2020	N/A	-17	-17	-17	N/A
3/31/2020	N/A	-18	-18	-18	N/A
12/31/2019	N/A	-7	-18	-18	N/A
9/30/2019	N/A	-5	-13	-13	N/A
6/30/2019	N/A	0	-9	-9	N/A
3/31/2019	N/A	4	-5	-5	N/A
12/31/2018	N/A	-4	-2	-2	N/A
9/30/2018	N/A	-2	-2	-2	N/A
12/31/2017	N/A	-3	-3	-3	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que PDSB siga sin ser rentable en los próximos 3 años.

Beneficios vs. Mercado: Se prevé que PDSB siga sin ser rentable en los próximos 3 años.

Beneficios de alto crecimiento: Se prevé que PDSB siga sin ser rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que PDSB no tenga ingresos el año que viene.

Ingresos de alto crecimiento: Se prevé que PDSB no tenga ingresos el año que viene.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de PDSB se prevé que sea elevada dentro de 3 años.

PDS Biotechnology Crecimiento futuro

Future controles de criterios 0/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Price target decreased by 8.4% to US$17.67

Price target increased by 7.9% to US$19.43

Price target increased to US$18.25

Price target increased to US$18.00

Price target decreased to US$17.71

Price target increased to US$20.50

Recent updates

PDS Biotechnology Corporation Appoints Stephan Toutain as Chief Operating Officer

PDS Biotechnology Corporation, Annual General Meeting, Jun 24, 2024

New minor risk - Market cap size

New minor risk - Shareholder dilution

PDS Biotechnology Corporation to Report Fiscal Year 2023 Results on Mar 27, 2024

PDS Biotechnology Corporation Announces Publication of Preclinical Research

PDS Biotechnology Corporation Announces Executive Changes

PDS Biotechnology: Promising Phase 2 With Cash Issues That Might Be Worth The Risk

Pds Biotech Announces CFO Changes

Price target decreased by 8.4% to US$17.67

PDS Biotech Announces Updated Survival Data from NCI-Led Phase 2 Clinical Trial of Pds0101-Based Triple Combination Therapy in Advanced Hpv16-Positive Cancer Patients

PDS Biotechnology Corporation to Report Q3, 2023 Results on Nov 14, 2023

PDS Biotechnology Corporation Announces Preliminary Biomarker Study Results in Subset of Advanced HPV-Positive Head and Neck Cancer Patients At ESMO

PDS Biotechnology Corporation Announces Interim Safety and Immune Response Data from Phase 1/2 Clinical Trial Evaluating Novel Antibody Drug Conjugate PDS0301 Combined with Docetaxel to Treat Metastatic Prostate Cancer

New major risk - Financial position

PDS Biotechnology Corporation Announces PDS0202 Elicits Active Neutralization of Multiple Influenza Strains in Preclinical Studies

PDS Biotech Announces Submission of Phase 3 Protocol to FDA to Initiate Versatile-003 Trial

PDS Biotechnology Corporation to Report Q2, 2023 Results on Aug 14, 2023

PDS Biotechnology Corporation to Present Updated Immune Response Data from Combination of PDS0101 and KEYTRUDA in Head and Neck Cancer Patients at ESMO Congress 2023

PDS Biotechnology Corporation Strengthens Intellectual Property Portfolio Governing A Combination of Versamune®? and PDS0301

PDS Biotechnology Announces Achievement of Efficacy Threshold in Stage 2 of the Versatile-002 Trial Evaluating Pds0101 and Keytruda in Head and Neck Cancer

PDS Biotechnology Corporation, Annual General Meeting, Jul 14, 2023

PDS Biotechnology Corporation Announces Interim Data Demonstrates 12-Month Survival Rate of 87% with PDS0101 in Combination with Keytruda (Pembrolizumab) for Head and Neck Cancer Patients

Pds Biotech Completes Enrollment in Immune Checkpoint Inhibitor Naïve Arm of Versatile-002 Phase 2 Clinical Trial in Advanced Hpv16 Positive Head and Neck Cancer

PDS Biotechnology Corporation to Report Q1, 2023 Results on May 15, 2023

Insufficient new directors

Price target increased by 7.9% to US$19.43

PDS Biotechnology Corporation Announces Preclinical Publication in Peer Reviewed Viruses Journal Showing Superior CD4 T Cell Induction by Infectimune

PDS Biotechnology Corporation Announces Preclinical Studies Involving Infectimune

PDS Biotechnology Corporation Announces Abstract Accepted for Presentation At ESMO Targeted Anticancer Therapies Congress

PDS Biotechnology Corporation Reports Median Overall Survival of 21 Months in Advanced, Refractory Cancer Patients Having Few Remaining Treatment Options and with Reported Historical Survival of 3-4 Months

Price target increased to US$18.25

PDS Biotech Completes First Stage of Enrollment in Checkpoint Inhibitor Refractory Arm of Phase 2 Clinical Trial in Advanced Hpv16 Positive Head and Neck Cancer

President exercised options and sold US$562k worth of stock

Price target increased to US$18.00

PDS Biotechnology Corporation Announces 100% Clinical Response in Cervical Cancer Patients in Preliminary Data from Immunocerv Phase 2 Clinical Trial

PDS Biotechnology Corporation Announces Presentation of Preliminary PDS0101 Efficacy, Safety, and Immunology Data at Society for Immunotherapy of Cancer (SITC 2022)

PDS Biotechnology Corporation to Report Q3, 2022 Results on Nov 14, 2022

PDS Biotech Announces Abstract Demonstrating Versatility of the Versamune® Platform in Oncology Accepted for Presentation at AACR Special Conference on Tumor Immunology and Immunotherapy

PDS Biotechnology Corporation Announces Expanded Interim Data in PDS0101 Triple Combination Phase 2 Trial Targeting Advanced HPV-Positive Cancers

Price target decreased to US$17.71

PDS Biotechnology Corporation Announces Successful End-of-Phase 2 Meeting With the FDA and Preparation for the Registrational Trial of PDS0101 in Combination With KEYTRUDA(R)

PDS Biotech jumps 13% as FDA clears further development of lead asset

PDS Biotechnology Corporation Biotech and National Cancer Institute Identify Optimal Patient Group for Advancing PDS0101-Based Triple Combination Program Targeting Advanced HPV-Positive Cancers

PDS Biotechnology files for $150 mixed shelf offering

PDS Biotech Independent Data Monitoring Committee Recommends Versatile-002 Trial Continuation Without Modifications

PDS Biotech spikes as panel backs continuation of cancer trial for lead asset

PDS Biotechnology Corporation to Report Q2, 2022 Results on Aug 08, 2022

PDS Biotechnology Corporation Announces Presentation of Universal Flu Vaccine Preclinical Data At American Society of Virology Meeting

PDS Biotechnology (NASDAQ:PDSB) Is In A Strong Position To Grow Its Business

PDS Biotechnology Corporation Appoints Spencer Brown as Senior Vice President, General Counsel

U.S. Food and Drug Administration Grants PDS Biotechnology Fast Track Designation for Lead Candidate Pds0101

PDS Biotechnology Corporation Announces Expansion of Its VERSATILE-002 Clinical Trial into Europe

PDS Biotechnology: Speculative Biotech Worth Buying After Latest Data

PDS Biotechnology Corporation Announces Presentation of Efficacy and Safety Data from VERSATILE-002 Phase 2 Clinical Trial in Recurrent or Metastatic Head and Neck Cancer At Asco 2022

PDS Biotechnology Corporation Appoints Sanjay Zaveri as Senior Vice President, Business Development

PDS Biotechnology Corporation, Annual General Meeting, Jun 15, 2022

PDS Biotech Announces Two Abstracts Accepted for Presentation at the 2022 American Society of Clinical Oncology Annual Meeting

Price target increased to US$20.50

No longer forecast to breakeven

PDS Biotech Announces Preliminary Safety Data on PDS0101 in Combination With KEYTRUDA® (pembrolizumab) at the 2022 Multidisciplinary Head and Neck Cancers Symposium

PDS Biotechnology: Versamune Platform Targeting HPV-Associated Cancers

PDS Biotechnology Corporation Announces Clinical Trial with Mayo Clinic to Study PDS0101 in Early Stage Pre-Metastatic- HPV-Associated Head and Neck Cancer

PDS Biotechnology Corporation Announces Preliminary Efficacy Achievement in VERSATILE-002 Phase 2 Trial of PDS0101 in Combination With KEYTRUDA® (pembrolizumab) in Advanced Head and Neck Cancer

PDS Biotech Announces Preclinical Data for PDS0202 Universal Influenza Vaccine

PDS Biotech Announces Presentation of PDS0101 Data at the 2022 Multidisciplinary Head and Neck Cancers Symposium

Forecast to breakeven in 2024

Price target increased to US$20.50

PDS Biotechnology Corporation Announces Phase 2 Clinical Trial Update